J
James E. Crowe
Researcher at Vanderbilt University Medical Center
Publications - 474
Citations - 28924
James E. Crowe is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Epitope & Monoclonal antibody. The author has an hindex of 83, co-authored 430 publications receiving 22045 citations. Previous affiliations of James E. Crowe include Government of the United States of America & Monroe Carell Jr. Children's Hospital at Vanderbilt.
Papers
More filters
Journal ArticleDOI
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Seth J. Zost,Pavlo Gilchuk,James Brett Case,Elad Binshtein,Rita E. Chen,Joseph P. Nkolola,Alexandra Schäfer,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,David R. Martinez,Lauren E. Williamson,Elaine C. Chen,Taylor Jones,Samuel Day,Luke Myers,Ahmed O. Hassan,Natasha M. Kafai,Emma S. Winkler,Julie M. Fox,Swathi Shrihari,Benjamin K. Mueller,Jens Meiler,Jens Meiler,Abishek Chandrashekar,Noe B. Mercado,James J. Steinhardt,Kuishu Ren,Yueh-Ming Loo,Nicole L. Kallewaard,Broc T. McCune,Shamus P. Keeler,Michael J. Holtzman,Dan H. Barouch,Lisa E. Gralinski,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +41 more
TL;DR: An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
Journal ArticleDOI
Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children.
John V. Williams,Paul A. Harris,Sharon J. Tollefson,Lisa L. Halburnt-Rush,Joyce M. Pingsterhaus,Kathryn M. Edwards,Peter F. Wright,James E. Crowe +7 more
TL;DR: Human metapneumovirus infection is a leading cause of respiratory tract infection in the first years of life, with a spectrum of disease similar to that of respiratory syncytial virus.
Journal ArticleDOI
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.
Allison J. Greaney,Allison J. Greaney,Tyler N. Starr,Pavlo Gilchuk,Seth J. Zost,Elad Binshtein,Andrea N. Loes,Andrea N. Loes,Sarah K Hilton,John Huddleston,Rachel Eguia,Katharine H.D. Crawford,Katharine H.D. Crawford,Adam S. Dingens,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,Paul W. Rothlauf,Paul W. Rothlauf,Zhuoming Liu,Sean P. J. Whelan,Robert H. Carnahan,Robert H. Carnahan,James E. Crowe,James E. Crowe,Jesse D. Bloom,Jesse D. Bloom,Jesse D. Bloom +27 more
TL;DR: A deep mutational scanning method is described to map how all amino-acid mutations in the RBD affect antibody binding, and this method is applied to 10 human monoclonal antibodies to enable rational design of antibody therapeutics and assessment of the antigenic consequences of viral evolution.
Journal ArticleDOI
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
Rita E. Chen,Xianwen Zhang,James Brett Case,Emma S. Winkler,Yang Liu,Laura A. VanBlargan,Jianying Liu,John M. Errico,Xuping Xie,Naveenchandra Suryadevara,Pavlo Gilchuk,Seth J. Zost,Stephen Tahan,Lindsay Droit,Jackson S. Turner,Wooseob Kim,Aaron J. Schmitz,Mahima Thapa,David Wang,Adrianus C. M. Boon,Rachel M. Presti,Jane A. O’Halloran,Alfred H.J. Kim,Parakkal Deepak,Dora Pinto,Daved H. Fremont,James E. Crowe,Davide Corti,Herbert W. Virgin,Herbert W. Virgin,Ali H. Ellebedy,Pei Yong Shi,Michael S. Diamond +32 more
TL;DR: In this article, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, the authors report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants.
Journal ArticleDOI
Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus
TL;DR: Crystal structures of the virus envelope protein, hemagglutinin, from 2009 H1N1 and of 1918 H1 HA in complex with a neutralizing antibody that cross-reacts with both pandemic viruses reveal an epitope that is conserved in the pandemic virus, but divergent in other known H1 HAs, from the 1930s to the present.